IMMP2L and cranioectodermal dysplasia: To date, no likely pathogenic or pathogenic variants have been described in IMMP2L. Taken together, further clinical data and functional experiments are needed to verify the correlation between the detected microdeletion and the clinical phenotype of the CED patient.